Search results
Results From The WOW.Com Content Network
Pfizer (PFE) suffers massively in 2019 due to aggressive business development activity, incremental currency woes and loss of exclusivity of key drug Lyrica. But it is poised to have a better 2020.
Pfizer posted a 45 percent jump in third-quarter profit, as the biggest U.S.-based drugmaker benefited from sharply lower taxes due to this year's federal tax cut. The maker of Viagra and nerve ...
Pfizer's (PFE) fourth-quarter earnings and sales beat estimates. Its forecast for 2019 falls short of expectations. Stock dips 2% in pre-market trading.
Despite constant attempts by analysts and the media to complicate the basics of investing, there are really only three ways a stock can create value for its shareholders: Dividends. Earnings growth.
Pfizer last year renegotiated a U.S. contract, allowing the government to return unused Paxlovid inventory. It recorded a $771 million favorable adjustment in the quarter, related to the U.S ...
Pfizer (PFE) performs better than the industry in 2018 and looks well poised to keep the positive momentum alive in 2019.
AlamyBy Arthur Allen | KHNThe grinding two-plus years of the pandemic have yielded outsize benefits for one company—Pfizer—making it both highly influential and hugely profitable as covid-19 ...
For premium support please call: 800-290-4726 more ways to reach us